RECRUITINGINTERVENTIONAL

Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea

Effect of Fan Application in Preventing Ticagrelor-associated Dyspnea in Patients With Acute Coronary Syndrome.

About This Trial

This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.

Who May Be Eligible (Plain English)

Who May Qualify: - Between the ages of 18 and 65, - No severe hearing and vision problems, - Can speak and understand Turkish, - Easy to communicate with, - First-time sufferer of acute coronary syndrome (ACS) for the first time, - Decided to start ticagrelor therapy, - Able to adapt to treatment, - Individuals who volunteered to participate in the research. Who Should NOT Join This Trial: - Having any problem that prevents you from communicating cognitively, emotionally and verbally, - Obstructive sleep abnormalities, - Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), - With metabolic abnormalities, - Intubated after the procedure, - Previously treated with ticagrelor, - Individuals who did not volunteer to participate in the study. Losses to follow up - Individuals who wish to leave the study voluntarily. - Saturation value below 95%, - The one with the arrest, - Who will not be able to fulfill the requirements of the work, - Individuals with life-threatening conditions Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Between the ages of 18 and 65, * No severe hearing and vision problems, * Can speak and understand Turkish, * Easy to communicate with, * First-time sufferer of acute coronary syndrome (ACS) for the first time, * Decided to start ticagrelor therapy, * Able to adapt to treatment, * Individuals who volunteered to participate in the research. Exclusion Criteria: * Having any problem that prevents you from communicating cognitively, emotionally and verbally, * Obstructive sleep abnormalities, * Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), * With metabolic abnormalities, * Intubated after the procedure, * Previously treated with ticagrelor, * Individuals who did not volunteer to participate in the study. Losses to follow up * Individuals who wish to leave the study voluntarily. * Saturation value below 95%, * The one with the arrest, * Who will not be able to fulfill the requirements of the work, * Individuals with life-threatening conditions

Treatments Being Tested

OTHER

STANDART CARE

Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.

OTHER

STANDART CARE & FAN THERAPY

In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \~15 cm. Dyspnea severity and number of episodes will be recorded during this period.

Locations (2)

İstanbul Üniversitesi-Cerrahapaşa

Istanbul, Avcılar, Turkey (Türkiye)

Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi

Istanbul, Üsküdar, Turkey (Türkiye)